Biosimilar User Fee Forecast: Unchanged Or Lower In FY 2019, US FDA Says

Absence of any fee increases reflects growing numbers of both approved biosimilars and products under development, as well as agency’s commitment to start spending down some of the carryover balance from prior years’ fee collections.